GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Price-to-Owner-Earnings

Genscript Biotech (HKSE:01548) Price-to-Owner-Earnings : (As of May. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Price-to-Owner-Earnings?

As of today (2024-05-28), Genscript Biotech's share price is HK$10.32. Genscript Biotech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Genscript Biotech's Price-to-Owner-Earnings or its related term are showing as below:

During the past 10 years, the highest Price-to-Owner-Earnings of Genscript Biotech was 16.94. The lowest was 8.43. And the median was 13.98.


HKSE:01548's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.11
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-28), Genscript Biotech's share price is HK$10.32. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.36. Therefore, Genscript Biotech's PE Ratio for today is At Loss.

As of today (2024-05-28), Genscript Biotech's share price is HK$10.32. Genscript Biotech's EPS without NRI for the trailing twelve months (TTM) ended in was HK$-0.44. Therefore, Genscript Biotech's PE Ratio without NRI for today is At Loss.

During the past 10 years, Genscript Biotech's highest PE Ratio without NRI was 268.26. The lowest was 0.00. And the median was 102.26.


Genscript Biotech Price-to-Owner-Earnings Historical Data

The historical data trend for Genscript Biotech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Price-to-Owner-Earnings Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genscript Biotech's Price-to-Owner-Earnings

For the Biotechnology subindustry, Genscript Biotech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genscript Biotech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's Price-to-Owner-Earnings falls into.



Genscript Biotech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genscript Biotech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=10.32/-0.66
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech  (HKSE:01548) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genscript Biotech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genscript Biotech (HKSE:01548) Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Executives
Wang Luquan 2401 A concert party to an agreement to buy shares
Wang Ye 2101 Beneficial owner
Zhang Fangliang 2401 A concert party to an agreement to buy shares
Huang Lili 2202 Interest of your spouse
Hu Zhiyong 2201 Interest of corporation controlled by you
Jin Weihong 2201 Interest of corporation controlled by you
Genscript Corporation 2101 Beneficial owner
Hillhouse Fund V, L.p. 2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Gns Holdings Limited 2101 Beneficial owner
Hillhouse Capital Management V, Ltd. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines